Eton Pharmaceuticals (ETON) Price & Analysis

Compare

508 Followers

ETON Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.25 - $23.00

Previous CloseN/A

Volume127.06K

Average Volume (3M)301.78K

Market Cap

$555.93M

Enterprise Value$388.54M

Total Cash (Recent Filing)$25.38M

Total Debt (Recent Filing)$3.26M

Price to Earnings (P/E)―

Beta1.35

Next Earnings

Nov 12, 2025

EPS Estimate

0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding26,817,535

10 Day Avg. Volume462,959

30 Day Avg. Volume301,777

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.70

Enterprise Value/Revenue6.68

Enterprise Value/Gross Profit11.24

Enterprise Value/Ebitda20.45K

Forecast

1Y Price Target

$30.00

Price Target Upside41.84% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentIf Increlex receives a new label that expands the eligible population, the peak revenue potential could grow five-fold to nearly $300M.

Product AdoptionThe adoption of Galzin is off to a good start, and Eton plans to introduce a long-acting formulation, ET-700, which could further enhance its market potential.

Revenue GrowthManagement now expects to reach their target revenue run rate of $80M in 3Q25, a quarter earlier than their prior expectation.

Bears Say

Risk FactorsRisks to the Buy rating include clinical, commercial, collaboration, dilution, legal and intellectual property, and competition.

Eton Pharmaceuticals News

Eton Pharmaceuticals management to meet virtually with Craig-Hallum

Virtual Meeting to be held on September 25 hosted by Craig-Hallum. Published first on TheFly – the ultimate...

22d ago

ETON

Eton Pharmaceuticals Reports Strong Q2 Growth Amid Challenges

Eton Pharmaceuticals (($ETON)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

ETON

Eton Pharmaceuticals Reports Robust Q2 2025 Growth

Eton Pharmaceuticals ( ($ETON) ) has released its Q2 earnings. Here is a breakdown of the information Eton...

2M ago

ETON

Eton Pharmaceuticals reports Q2 non-GAAP EPS 3c, consensus 2c

Reports Q2 revenue $18.9M, consensus $16.71M. “Eton continues to execute on all fronts. During the second quarter, we...

2M ago

ETON

Eton Pharmaceuticals sees reaching annual revenue run rate of $80M in Q3

16:37 EDT Eton Pharmaceuticals (ETON) sees reaching annual revenue run rate of $80M in Q3 Published first on...

2M ago

ETON

Eton Pharmaceuticals’ ET-600 Launch and Strategic Expansion Drive Buy Rating

H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on ETON stock, giving a Buy rating yesterday....

3M ago

ETON

Eton Pharmaceuticals’ New Drug Application Accepted by FDA

An announcement from Eton Pharmaceuticals ( ($ETON) ) is now available. On July 8, 2025, Eton Pharmaceuticals announced...

3M ago

ETON

Eton Pharmaceuticals’ NDA for ET-600 solution accepted by FDA

Eton Pharmaceuticals (ETON) announced the company’s New Drug Application, or NDA, for ET-600, a proprietary patented formulation of...

3M ago

ETON

Eton Pharmaceuticals management to meet with B. Riley

Meeting to be held in San Francisco on July 14 hosted by B. Riley. Published first on TheFly...

3M ago

ETON

Eton Pharmaceuticals Joins Russell 3000 and 2000 Indexes

Eton Pharmaceuticals ( ($ETON) ) has issued an update. On June 27, 2025, Eton Pharmaceuticals announced its inclusion...

3M ago

ETON

Eton Pharmaceuticals to be added to Russell 2000, Russell 3000 Indexes

Eton Pharmaceuticals (ETON) announced that it will be added to the broad-market Russell 3000 and small-cap Russell 2000...

3M ago

ETON

Eton Pharmaceuticals Holds Annual Stockholders Meeting

Eton Pharmaceuticals ( ($ETON) ) has shared an update. On June 10, 2025, Eton Pharmaceuticals, Inc. held its...

4M ago

ETON

Eton Pharmaceuticals price target raised to $35 from $33 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $35 from $33 and keeps a...

4M ago

ETON

Eton Pharmaceuticals: Buy Rating Affirmed on Khindivi’s FDA Approval and Strong Revenue Growth Prospects

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Eton Pharmaceuticals (ETON – Research Report), boosting...

4M ago

ETON

ETON FAQ

What was Eton Pharmaceuticals Inc’s price range in the past 12 months?

Eton Pharmaceuticals Inc lowest stock price was $7.25 and its highest was $23.00 in the past 12 months.

What is Eton Pharmaceuticals Inc’s market cap?

Eton Pharmaceuticals Inc’s market cap is $555.93M.

When is Eton Pharmaceuticals Inc’s upcoming earnings report date?

Eton Pharmaceuticals Inc’s upcoming earnings report date is Nov 12, 2025 which is in 34 days.

How were Eton Pharmaceuticals Inc’s earnings last quarter?

Eton Pharmaceuticals Inc released its earnings results on Aug 07, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.037 by -$0.063.

Is Eton Pharmaceuticals Inc overvalued?

According to Wall Street analysts Eton Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Eton Pharmaceuticals Inc pay dividends?

Eton Pharmaceuticals Inc does not currently pay dividends.

What is Eton Pharmaceuticals Inc’s EPS estimate?

Eton Pharmaceuticals Inc’s EPS estimate is 0.09.

How many shares outstanding does Eton Pharmaceuticals Inc have?

Eton Pharmaceuticals Inc has 26,817,535 shares outstanding.

What happened to Eton Pharmaceuticals Inc’s price movement after its last earnings report?

Eton Pharmaceuticals Inc reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.037. Following the earnings report the stock price went up 12.32%.

Which hedge fund is a major shareholder of Eton Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ETON

Eton Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-22.06%

Trailing 12-Months

Asset Growth

219.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals (ETON) Earnings & Revenues

Historic Earnings Reports

ETON Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a positive outlook with several major achievements in product sales, FDA approvals, and financial performance, despite some challenges related to product labeling and regulatory hurdles.View all ETON earnings summaries

ETON Stock 12 Month Forecast

Average Price Target

$30.00

▲(41.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","36":"$36","11.25":"$11.25","19.5":"$19.5","27.75":"$27.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,11.25,19.5,27.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.19,18.560000000000002,19.93,21.3,22.67,24.04,25.41,26.78,28.15,29.52,30.89,32.26,33.629999999999995,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.19,18.175384615384615,19.160769230769233,20.146153846153847,21.13153846153846,22.11692307692308,23.102307692307694,24.087692307692308,25.073076923076925,26.05846153846154,27.043846153846154,28.02923076923077,29.014615384615386,{"y":30,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.19,17.86769230769231,18.545384615384616,19.223076923076924,19.90076923076923,20.57846153846154,21.256153846153847,21.933846153846154,22.611538461538462,23.28923076923077,23.966923076923077,24.644615384615385,25.322307692307692,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.91,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.68,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >